My watch list

Pralatrexate

This article needs additional citations for verification.
Please help improve this article by adding reliable references. Unsourced material may be challenged and removed. (June 2007)


Pralatrexate
Systematic (IUPAC) name
N-[4-[1-[(2,4-Diamino-6-pteridinyl)methyl] -3-butynyl]benzoyl]-L-glutamic acid
Identifiers
CAS number	146464-95-1
ATC code	?
PubChem	725808
Chemical data
Formula	C₂₃H₂₃N₇O₅
Mol. mass	477.47 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Pralatrexate (rINN), also known as 10-propargyl-10-deazaaminopterin, common name PDX, is a drug candidate being studied for the treatment of cancer. PDX is a folate analog inhibitor of dihydrofolate reductase. As of July 2005, it is undergoing Phase 1 and Phase 2 clinical trials for treatment of non-Hodgkin lymphoma and non-small cell lung cancer.